Neuroprotective potential of isofraxidin: Alleviating parkinsonian symptoms, inflammation and microglial activation

Background Parkinson’s disease (PD) is one of the most common neurodegenerative disorders. Previous research has confirmed that isofraxidin can reduce macrophage expression and inhibit peripheral inflammation. However, its effects on the central nervous system remain underexplored. Objective This st...

Full description

Saved in:
Bibliographic Details
Main Authors: Tin-An Wang, Shiao-Yun Li, Li-Yun Fann, I-Hsun Li, Tsung-Ta Liu, Hao-Yuan Hung, Chieh-Wen Chang, Chih-Chien Cheng, Ying-Che Huang, Pei-Yeh Yu, Jui-Hu Shih
Format: Article
Language:English
Published: SAGE Publishing 2025-01-01
Series:Journal of Central Nervous System Disease
Online Access:https://doi.org/10.1177/11795735241312661
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841552427806883840
author Tin-An Wang
Shiao-Yun Li
Li-Yun Fann
I-Hsun Li
Tsung-Ta Liu
Hao-Yuan Hung
Chieh-Wen Chang
Chih-Chien Cheng
Ying-Che Huang
Pei-Yeh Yu
Jui-Hu Shih
author_facet Tin-An Wang
Shiao-Yun Li
Li-Yun Fann
I-Hsun Li
Tsung-Ta Liu
Hao-Yuan Hung
Chieh-Wen Chang
Chih-Chien Cheng
Ying-Che Huang
Pei-Yeh Yu
Jui-Hu Shih
author_sort Tin-An Wang
collection DOAJ
description Background Parkinson’s disease (PD) is one of the most common neurodegenerative disorders. Previous research has confirmed that isofraxidin can reduce macrophage expression and inhibit peripheral inflammation. However, its effects on the central nervous system remain underexplored. Objective This study aims to determine whether isofraxidin offers protective effects against PD. Methods To assess the effects of isofraxidin, motor performance changes in LPS-induced PD mice were evaluated using rotarod, pole-climbing, and beam-walking tests. Striatal damage was examined through [ 18 F]fluorodeoxyglucose ([ 18 F]FDG) positron emission tomography (PET) imaging, and dopaminergic neurotoxicity was assessed using tyrosine hydroxylase (TH) staining. Microglial accumulation and activation were monitored with Iba-1 staining, while LPS-induced inflammation was examined via TNF-α and IL-1β staining. Results Isofraxidin pre-treatment significantly improved LPS-induced motor dysfunction, as evidenced by better performance in the rotarod, pole-climbing, and beam-walking tests. [ 18 F]FDG PET imaging showed that isofraxidin restored glucose uptake in the striatum, countering LPS-induced damage. Furthermore, Iba-1 staining revealed that isofraxidin markedly inhibited LPS-induced microglial activation and accumulation. TNF-α and IL-1β staining indicated a reduction in inflammation with isofraxidin treatment. Additionally, TH staining supported the neuroprotective role of isofraxidin on dopaminergic neurons. Conclusions Isofraxidin exhibits notable neuroprotective properties by mitigating LPS-induced parkinsonian behaviors, microglial activation, inflammation, and dopaminergic neuron damage. These results highlight isofraxidin’s potential as a therapeutic intervention for PD.
format Article
id doaj-art-89bf6e5b92ad419997b3b9b4bc2df632
institution Kabale University
issn 1179-5735
language English
publishDate 2025-01-01
publisher SAGE Publishing
record_format Article
series Journal of Central Nervous System Disease
spelling doaj-art-89bf6e5b92ad419997b3b9b4bc2df6322025-01-09T13:03:19ZengSAGE PublishingJournal of Central Nervous System Disease1179-57352025-01-011710.1177/11795735241312661Neuroprotective potential of isofraxidin: Alleviating parkinsonian symptoms, inflammation and microglial activationTin-An WangShiao-Yun LiLi-Yun FannI-Hsun LiTsung-Ta LiuHao-Yuan HungChieh-Wen ChangChih-Chien ChengYing-Che HuangPei-Yeh YuJui-Hu ShihBackground Parkinson’s disease (PD) is one of the most common neurodegenerative disorders. Previous research has confirmed that isofraxidin can reduce macrophage expression and inhibit peripheral inflammation. However, its effects on the central nervous system remain underexplored. Objective This study aims to determine whether isofraxidin offers protective effects against PD. Methods To assess the effects of isofraxidin, motor performance changes in LPS-induced PD mice were evaluated using rotarod, pole-climbing, and beam-walking tests. Striatal damage was examined through [ 18 F]fluorodeoxyglucose ([ 18 F]FDG) positron emission tomography (PET) imaging, and dopaminergic neurotoxicity was assessed using tyrosine hydroxylase (TH) staining. Microglial accumulation and activation were monitored with Iba-1 staining, while LPS-induced inflammation was examined via TNF-α and IL-1β staining. Results Isofraxidin pre-treatment significantly improved LPS-induced motor dysfunction, as evidenced by better performance in the rotarod, pole-climbing, and beam-walking tests. [ 18 F]FDG PET imaging showed that isofraxidin restored glucose uptake in the striatum, countering LPS-induced damage. Furthermore, Iba-1 staining revealed that isofraxidin markedly inhibited LPS-induced microglial activation and accumulation. TNF-α and IL-1β staining indicated a reduction in inflammation with isofraxidin treatment. Additionally, TH staining supported the neuroprotective role of isofraxidin on dopaminergic neurons. Conclusions Isofraxidin exhibits notable neuroprotective properties by mitigating LPS-induced parkinsonian behaviors, microglial activation, inflammation, and dopaminergic neuron damage. These results highlight isofraxidin’s potential as a therapeutic intervention for PD.https://doi.org/10.1177/11795735241312661
spellingShingle Tin-An Wang
Shiao-Yun Li
Li-Yun Fann
I-Hsun Li
Tsung-Ta Liu
Hao-Yuan Hung
Chieh-Wen Chang
Chih-Chien Cheng
Ying-Che Huang
Pei-Yeh Yu
Jui-Hu Shih
Neuroprotective potential of isofraxidin: Alleviating parkinsonian symptoms, inflammation and microglial activation
Journal of Central Nervous System Disease
title Neuroprotective potential of isofraxidin: Alleviating parkinsonian symptoms, inflammation and microglial activation
title_full Neuroprotective potential of isofraxidin: Alleviating parkinsonian symptoms, inflammation and microglial activation
title_fullStr Neuroprotective potential of isofraxidin: Alleviating parkinsonian symptoms, inflammation and microglial activation
title_full_unstemmed Neuroprotective potential of isofraxidin: Alleviating parkinsonian symptoms, inflammation and microglial activation
title_short Neuroprotective potential of isofraxidin: Alleviating parkinsonian symptoms, inflammation and microglial activation
title_sort neuroprotective potential of isofraxidin alleviating parkinsonian symptoms inflammation and microglial activation
url https://doi.org/10.1177/11795735241312661
work_keys_str_mv AT tinanwang neuroprotectivepotentialofisofraxidinalleviatingparkinsoniansymptomsinflammationandmicroglialactivation
AT shiaoyunli neuroprotectivepotentialofisofraxidinalleviatingparkinsoniansymptomsinflammationandmicroglialactivation
AT liyunfann neuroprotectivepotentialofisofraxidinalleviatingparkinsoniansymptomsinflammationandmicroglialactivation
AT ihsunli neuroprotectivepotentialofisofraxidinalleviatingparkinsoniansymptomsinflammationandmicroglialactivation
AT tsungtaliu neuroprotectivepotentialofisofraxidinalleviatingparkinsoniansymptomsinflammationandmicroglialactivation
AT haoyuanhung neuroprotectivepotentialofisofraxidinalleviatingparkinsoniansymptomsinflammationandmicroglialactivation
AT chiehwenchang neuroprotectivepotentialofisofraxidinalleviatingparkinsoniansymptomsinflammationandmicroglialactivation
AT chihchiencheng neuroprotectivepotentialofisofraxidinalleviatingparkinsoniansymptomsinflammationandmicroglialactivation
AT yingchehuang neuroprotectivepotentialofisofraxidinalleviatingparkinsoniansymptomsinflammationandmicroglialactivation
AT peiyehyu neuroprotectivepotentialofisofraxidinalleviatingparkinsoniansymptomsinflammationandmicroglialactivation
AT juihushih neuroprotectivepotentialofisofraxidinalleviatingparkinsoniansymptomsinflammationandmicroglialactivation